Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Absorption in Short-bowel Syndrome (GRAAL)
NCT05302531Phase 1Recruiting
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amoxicillin, ofloxacin, levofloxacin and trimethoprim + sulfamethoxazole in bacterial infection, sponsored by CHRU de Nancy - Hôpital Central. Started Dec 2022; status: recruiting.
02
Drugs
amoxicillinofloxacinlevofloxacintrimethoprim + sulfamethoxazole
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05302531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302531.